ArticlePediatric pulmonology2025
A Comparative Bibliometric Analysis of Pediatric Interstitial Lung Disease Treatment: Global Trends, Advances, and Future Directions (2004-2024).
Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChildhood interstitial lung disease (chILD) is rare, heterogeneous, and presents major treatment challenges. This bibliometric study analyzes research trends and hotspots specifically within the domain of chILD treatment research.
methodsUsing bibliometrics, this study utilized data from the Web of Science Core Collection spanning from 2004 to 2024. Various research hotspots were analyzed using VOSviewer, CiteSpace, and the R package "bibliometric."
resultsA total of 577 articles were examined. Prominent journals contributing to this field included Pediatric Pulmonology, Thorax, and the European Respiratory Journal. Griese Matthias, Schwerk Nicolaus, and Clement Annick emerged as the most productive and cited authors. The study identified five key research directions: (1) genetic and molecular mechanisms, (2) clinical management, (3) neonatal risk factors, (4) autoimmune-related factors and immunomodulatory therapies, and (5) fibrosis progression. Keyword analysis showed a recent surge (2022-2024) in research on autoimmune and inflammatory factors, with notable bursts in "polymyositis" and "juvenile dermatomyositis," alongside growing attention to immunosuppressive therapies such as "mycophenolate-mofetil." In contrast, pulmonary fibrosis and imaging-based diagnosis demonstrated limited recent activity, as "thin-section CT" and "high-resolution CT" maintained only a secondary role, reflecting a shift in focus toward immune-mediated mechanisms and therapeutic innovation.
conclusionAlthough the total number of chILD publications remains small, increasing attention to the field highlights the need for further contributions. Along with advances in understanding molecular pathogenesis, the recent surge of immunomodulatory therapies reflects a promising shift toward precision medicine through the identification and targeting of cellular mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.